Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress(AstraZeneca (United States)), Geoffrey R. Oxnard(Foundation Medicine (United States)), Yanan Kuang(Dana-Farber Cancer Institute), Sarah E Matthews(Dana-Farber Cancer Institute), Daniel Stetson(AstraZeneca (United States)), J. Carl Barrett(National Institute of Environmental Health Sciences), Pasi A. Jänne(Harvard University), Cloud P. Paweletz(Massachusetts General Hospital), Aleksandra Markovets(AstraZeneca (United States)), Byoung Chul Cho(Yonsei University), Mireille Cantarini(AstraZeneca (United Kingdom)), Ana Vivancos(Vall d'Hebron Institute of Oncology), Brian Dougherty(AstraZeneca (United States)), Dalia Ercan(Dana-Farber Cancer Institute), Enriqueta Felip(Institut Català d'Ornitologia), Zhongwu Lai(AstraZeneca (United States))
Cited by 1,537
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k